阿维鲁单抗一线维持治疗晚期尿路上皮癌的法国真实世界研究:AVENANCE非干预性研究总体结果及二线治疗结局分析
AVENANCE是一项在法国82个中心开展的回顾性及前瞻性非干预性研究,纳入595例铂类化疗后无进展的晚期尿路上皮癌患者,接受阿维鲁单抗一线维持治疗,中位随访26.3个月。从阿维鲁单抗起始的中位总生存期为21.3个月(95%CI 17.6-24.6),中位无进展生存期为5.7个月(95%CI 5.2-6.5)。真实世界数据支持阿维鲁单抗在顺铂适合及不适合患者中的推荐。
要点
- AVENANCE真实世界研究纳入595例铂类化疗后无进展的晚期尿路上皮癌患者,中位随访26.3个月。
- 从阿维鲁单抗起始的中位总生存期为21.3个月(95%CI 17.6-24.6),中位无进展生存期为5.7个月(95%CI 5.2-6.5)。
- 探索性分析中,接受二线恩诺单抗维多汀(n=55)或铂类化疗(n=79)亚组从一线铂类化疗起始的中位总生存期分别为41.5个月和24.5个月。
核心结论
- AVENANCE真实世界数据证实阿维鲁单抗一线维持治疗在异质性人群中有效且安全,支持其用于一线铂类化疗后无进展的顺铂适合及不适合的晚期尿路上皮癌患者。
- 探索性分析中,接受一线铂类化疗无进展后阿维鲁单抗一线维持治疗序贯二线恩诺单抗维多汀的小亚组中位总生存期超过3年。
研究设计与样本
- 回顾性及前瞻性非干预性研究(NCT04822350),2021年7月至2022年5月在法国82个中心入组一线铂类化疗后无进展的晚期尿路上皮癌患者,有效性人群595例,中位随访26.3个月。
主要发现
- 中位年龄73.0岁,体力状态0/1分占91%,≥2分占9.3%,最常见既往一线化疗方案为卡铂联合吉西他滨(61%)。
- 数据截止2023年12月7日,阿维鲁单抗中位治疗持续时间5.6个月,125例仍在接受阿维鲁单抗治疗,55%已接受二线治疗。
- 从阿维鲁单抗起始的中位总生存期为21.3个月(95%CI 17.6-24.6),中位无进展生存期为5.7个月(95%CI 5.2-6.5)。
- 探索性分析中,从一线铂类化疗起始的中位总生存期总体为26.5个月,二线恩诺单抗维多汀亚组(n=55)为41.5个月,二线铂类化疗亚组(n=79)为24.5个月。
临床怎么用
- 作者结论支持阿维鲁单抗一线维持治疗用于一线铂类化疗后无进展的顺铂适合及不适合的晚期尿路上皮癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Avelumab first-line maintenance treatment was approved for patients with advanced urothelial carcinoma (aUC) without progression following platinum-based chemotherapy (PBC), based on the results from the JAVELIN Bladder 100 phase 3 trial. OBJECTIVE: To report the results from AVENANCE, a real-world study of avelumab first-line maintenance treatment. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective and prospective, noninterventional study (NCT04822350). Eligible patients with aUC without progression on first-line PBC were enrolled at 82 centers in France between July 2021 and May 2022. The effectiveness population included 595 patients. The median follow-up was 26.3 mo. INTERVENTION: Previous, ongoing, or planned avelumab first-line maintenance treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS) from avelumab initiation (primary endpoint) and safety were evaluated. RESULTS AND LIMITATIONS: The median age was 73.0 yr, and performance status was 0/1 in 91% of patients and ≥2 in 9.3%. The most common prior first-line chemotherapy regimen was carboplatin plus gemcitabine (61%). At data cutoff (December 7, 2023), the median duration of avelumab treatment was 5.6 mo, 125 patients remained on avelumab, and 55% had received second-line treatment. The median OS from avelumab initiation was 21.3 mo (95% confidence interval [CI], 17.6-24.6), and the median progression-free survival was 5.7 mo (95% CI, 5.2-6.5). In exploratory analyses of this population without disease progression on PBC, the median OS from the start of first-line PBC was 26.5 mo overall, and in subgroups that received second-line enfortumab vedotin (n = 55) or PBC (n = 79), it was 41.5 and 24.5 mo, respectively. CONCLUSIONS: Real-world data from AVENANCE confirm the effectiveness and safety of avelumab first-line maintenance treatment in a heterogeneous population, supporting its recommendation for cisplatin-eligible and cisplatin-ineligible patients with aUC who are progression free after first-line PBC. In an exploratory analysis, a small subgroup that received a treatment sequence of first-line PBC without disease progression followed by avelumab first-line maintenance and second-line enfortumab vedotin had a median OS of >3 yr. PATIENT SUMMARY: A French real-world study, called AVENANCE, looked at avelumab maintenance treatment in people with advanced urothelial cancer whose tumor disappeared, shrank, or stopped growing with chemotherapy. Overall, results were consistent with those seen in a previous clinical trial, and on average, people treated with avelumab maintenance lived for 26.5 mo from the start of chemotherapy. Analyses of different groups of people found that survival varied, with people living for an average of 18-42 mo depending on what treatment they received after they finished avelumab treatment.
引用
- Barthélémy P, Thibault C, Fléchon A, et al. Real-world Study of Avelumab First-line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma in France: Overall Results from the Noninterventional AVENANCE Study and Analysis of Outcomes by Second-line Treatment. Eur Urol Oncol. 2024. PMID: 39448350. doi:10.1016/j.euo.2024.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。